# Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

> **NCT04288232** · PHASE3 · COMPLETED · sponsor: **Taipei Veterans General Hospital, Taiwan** · enrollment: 45 (actual)

## Conditions studied

- Center-involved Diabetic Macular Edema

## Interventions

- **DRUG:** Aflibercept Injection [Eylea]

## Key facts

- **NCT ID:** NCT04288232
- **Lead sponsor:** Taipei Veterans General Hospital, Taiwan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-31
- **Primary completion:** 2017-11-16
- **Final completion:** 2017-11-16
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288232, "Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04288232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*